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ARTICLE
Germline variants in POLE are associated with early
onset mismatch repair deficient colorectal cancer
Fadwa A Elsayed1, C Marleen Kets2, Dina Ruano1, Brendy van den Akker1, Arjen R Mensenkamp2,
Melanie Schrumpf1, Maartje Nielsen3, Juul T Wijnen3,4, Carli M Tops3, Marjolijn J Ligtenberg2,5,
Hans FA Vasen6, Frederik J Hes3, Hans Morreau1 and Tom van Wezel*,1
Germline variants affecting the exonuclease domains of POLE and POLD1 predispose to multiple colorectal adenomas and/or
colorectal cancer (CRC). The aim of this study was to estimate the prevalence of previously described heterozygous germline
variants POLE c.1270C4G, p.(Leu424Val) and POLD1 c.1433G4A, p.(Ser478Asn) in a Dutch series of unexplained familial,
early onset CRC and polyposis index cases. We examined 1188 familial CRC and polyposis index patients for POLE p.(Leu424Val)
and POLD1 p.(Ser478Asn) variants using competitive allele-specific PCR. In addition, protein expression of the POLE and DNA
mismatch repair genes was studied by immunohistochemistry in tumours from POLE carriers. Somatic mutations were screened
using semiconductor sequencing. We detected three index patients (0.25%) with a POLE p.(Leu424Val) variant. In one patient,
the variant was found to be de-novo. Tumours from three patients from two families were microsatellite instable, and
immunohistochemistry showed MSH6/MSH2 deficiency suggestive of Lynch syndrome. Somatic mutations but no germline MSH6
and MSH2 variants were subsequently found, and one tumour displayed a hypermutator phenotype. None of the 1188 patients
carried the POLD1 p.(Ser478Asn) variant. POLE germline variant carriers are also associated with a microsatellite instable CRC.
POLE DNA analysis now seems warranted in microsatellite instable CRC, especially in the absence of a causative DNA mismatch
repair gene germline variant.
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INTRODUCTION
Faithful DNA replication and the repair of errors are both essential for
the maintenance of genomic stability and suppression of
carcinogenesis.1 Duplication of genomes with high accuracy is
achieved through three mechanisms: the high selectivity of DNA
polymerases; exonucleolytic proofreading; and post replication mis-
match repair.2 The DNA polymerases ε (POLε) and δ (POLδ) are
required for the efficient genome replication in the eukaryotic
replication fork.3 Their major component proteins, encoded by POLE
and POLD1, respectively, possess an intrinsic 3′–5′ proofreading
domain that removes incorrectly inserted nucleotides during DNA
synthesis.4–9 Studies in the yeast have shown that mutations in the
proofreading domains of POLε or POLδ increase spontaneous
mutation rates.8,9 In addition, somatic mutations in the proofreading
domains of POLD1 and POLE have been identified in microsatellite
instable (MSI) and hypermutated subgroups of colorectal cancers
(CRCs).10–12
Recently, Palles et al reported that heterozygous germline variants in
the proofreading domain of the DNA polymerases POLE and POLD1
predispose, with a high penetrance, to multiple colorectal adenomas,
early onset CRC (OMIM #114500) and endometrial cancer (OMIM
#608089). These variants were found by whole-genome sequencing
and linkage analysis in three large families with a dominant pattern of
CRC and multiple adenomas.13 Subsequent screening of 3805 CRC
patients revealed that these variants are relatively rare: POLE
p.(Leu424Val) was found 12 times, and POLD1 p.(Ser478Asn) only
once, in patients with a positive family history of adenomas or CRC.
The tumours seen in POLE and POLD1 carriers were microsatellite
stable and showed a hypermutator phenotype.13 Valle et al14 detected a
single POLE p.(Leu424Val) variant in a screen of 858 familial/early
onset CRC and polyposis patients.
The goal of our study was to estimate the prevalence of germline
variants in POLE and POLD1 in a Dutch series of unexplained
familial, early onset CRC and polyposis index cases. In addition, we
analysed phenotypes and tumour characteristics in this patient series.
MATERIALS AND METHODS
Samples
DNA from index patients with colorectal polyposis15 and familial CRC16 was
analysed for POLE NM_006231.2:c.1270C4G, p.(Leu424Val) and POLD1
NM_002691.1:c.1433G4A, p.(Ser478Asn). Leucocyte DNA from 485 polyposis
cases was included. These patients had developed ≥ 10 colorectal adenomas and
had been previously tested negative for APC and MUTYH germline mutations
at the Laboratory for Diagnostic Genome Analysis in Leiden. Clinical data were
collected from the Netherlands Foundation for the Detection of Hereditary
Tumours and from clinical genetics departments in the Netherlands.17 The
familial CRC cohort comprised 703 patients, mainly from the south-western
region of the Netherlands, with most cases submitted by clinical genetics
departments. These patients met clinical criteria for MSI testing, which are
based on early onset of disease and/or familial clustering of CRC and associated
cancers, corresponding to the revised Bethesda criteria. Samples were collected
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between 1997 and 2013, and DNA for this cohort was available from peripheral
blood (340 cases) or from formalin-fixed paraffin embedded normal mucosa
(363 cases). These samples were described before, only DNA that passes quality
check was included in the study.16 The study was approved by the local medical
ethical committee of the Leiden University Medical Center (P01-019).
Genotyping
POLE p.(Leu424Val) and POLD1 p.(Ser478Asn) were tested using the
competitive allele-specific PCR (KASPar) assay, following the manufacturer’s
protocol (LGC Genomics, Berlin, Germany). The primers were designed using
Primerpicker (KBioscience, Hoddesdon, UK). The following primers were used
to analyse POLE c.1270C4G: POLE_L424V_C1; 5′- GGA TCA TAG CCT
AGC TTG GCC TT–3′, POLE_L424V_A2; 5′–GAA GGT CGG AGT
CAA CGG ATT CCT TCC TGT GGG CAG TCA TAA TG–3′ and POLE_
L424V_A1; 5′–GAA GGT GAC CAA GTT CAT GCT CCT TCC TGT
GGG CAG TCA TAA TC–3′. For POLD1 c.1433G4A, we used: POLD1_
S478N_C2; 5′–TCT GCT CGC CCA GGA AGT GGA A–3′,
POLD1_S478N_A2; 5′–GAA GGT CGG AGT CAA CGG ATT CCT ACA CGC
TCA ATG CCG TGA A–3′ and POLD1_S478N_A1; 5′–GAA GGT GAC
CAA GTT CAT GCT ACA CGC TCA ATG CCG TGA G–3′.
Variants were identified using the CFX manager software v3.0 (Bio-Rad,
Veenendaal, the Netherlands). Formalin-fixed paraffin embedded and leucocyte
DNA samples were genotyped in separate experiments for accurate genotyping
results. Samples positive for POLE c.1270C4G, p.(Leu424Val) were subse-
quently validated by Sanger sequencing of leucocyte DNA and of DNA
extracted from formalin-fixed paraffin embedded tissues, using both normal
and tumour DNA where available. Sanger sequencing was performed by
Macrogen (Amsterdam, the Netherlands). The following primers, with
universal M13 tails (upper case), were used for POLE c.1270C4G; forward:
5′–TGT AAA ACG ACG GCC AGT cca tct gga tgc gtg cac a–3′ and reverse:
5′–CAG GAA ACA GCT ATG ACC gaa tca tcc tgg ctt ctg ttc tca–3′. For POLD1
validation we used the oligonucleotides, forward: 5′–TGT AAA ACG ACG GCC
AGT ctg tcc ttg gaa ggc cact–3′ and reverse: 5′–CAG GAA ACA GCT ATG
ACC gag gtc agg gag gca gca–3′. Sequencing primers were designed using
Primer3 (http://primer3.wi.mit.edu/) and all oligonucleotides were
manufactured by IDT (Leuven, Belgium).
The POLE p.(Leu424Val) carriers were submitted to the LOVD database
http://databases.lovd.nl/shared/genes/POLE, IDs 00019773 (PT1), 00019821
(PT2) 00019822 (PT3) and 00019824 (PT4).
Immunohistochemistry
Immunohistochemistry (IHC) for the DNA MMR proteins was performed as
previously described.18 POLE IHC was performed using 4 -μm thick, formalin-
fixed paraffin embedded tissue sections on StarFrost adhesive slides (Waldemar
Knittel, Braunschweig, Germany), dried overnight at 37 °C. Tissue sections
were deparaffinised three times in xylene for a total of 15min and subsequently
rehydrated with 100% ethanol three times for a total of 9min. Endogenous
peroxidase activity was blocked by immersing the tissue sections in a 0.3%
solution of hydrogen peroxide (H2O2) and methanol at room temperature for
20min. This treatment was followed by hydration in a graded ethanol series to
distilled water. Antigen retrieval was then performed by boiling the tissue
sections in 0.01M citrate buffer (pH 6.0) for 10min using a microwave oven,
after which the tissue sections were allowed to cool in the same buffer to room
temperature. The tissue sections were then washed twice with distilled water,
for 5 min each time, followed by two 5min washes in 1× phosphate buffered
saline. This was followed by the addition of the primary antibody (ab110876,
ABCAM, Cambridge UK, dilution 1:1600) and the incubation of the covered
slides overnight in a humid chamber at room temperature.
After three 5min washes in 1× phosphate buffered saline the next morning,
the tissue sections were incubated for 30min with horseradish peroxidase-
conjugated multimer secondary antibody (PowerVision Poly/HRP, DAKO,
Heverlee, Belgium). The slides then received three 5min rinses in 1×
phosphate buffered saline and the antigen–antibody reaction was visualised
using 3,3′-diaminobenzidine in chromogenic solution, applied for 10min. The
tissue sections were subsequently rinsed in distilled water and then stained with
haematoxylin for 20 s. The tissue sections were rinsed in running tap water for
5 min and washed twice with distilled water, followed by dehydration in a
graded ethanol series (50, 70 and 100%) and cleared in xylene. Finally, the
tissue sections were dried, mounted and covered for microscopic analysis.
Tissue stroma and normal epithelium or lymph follicles served as positive
internal controls while analysing POLE, MLH1, PMS2, MSH2 and MSH6
expression.
Somatic mutation screening
DNA from normal and tumour tissues of the POLE p.(Leu424Val) carriers PT1
and PT2 was screened for somatic mutations using a custom AmpliSeq panel
(Life Technologies Europe, Bleiswijk, the Netherlands) of the DNA mismatch
repair (MMR) genes MLH1, MSH2, MSH6, PMS2, supplemented with APC
and TP53. The panel was sequenced using the Ion PGM system at Leiden
Genome Technology Center, the Netherlands (www.lgtc.nl) and analysed with
the Nextgene Software package (Softgenetics, State College, PA, USA). MMR
DNA sequencing was performed as previously described in the case of PT3.19
Somatic KRAS and BRAF hotspot mutations (KRAS exons 2 and 3 and BRAF
p.V600E were tested as described previously.20 Somatic mutations are
submitted to the COSMIC database (ID # 616).
Methylation
MSH2 methylation was studied as described earlier using the MSP1 and MSP3
primer sets for both methylated and unmethylated DNA.21 DNA was
bisulfite treated using the EZ DNA methylation KIT (ZYMO Research Corp,
Irvine, CA, USA).
RESULTS AND DISCUSSION
We assessed the prevalence of POLE p.(Leu424Val) and POLD1
p.(Ser478Asn) in a cohort of 1188 Dutch index patients with multiple
polyps or familial CRC. All patients were originally referred for
possible FAP (OMIM #175100), MAP (OMIM #608456) or Lynch
syndrome (OMIM #120435) and no variants were found in the
relevant genes. Although we did not detect POLD1 p.(Ser478Asn),
three index patients with the POLE p.(Leu424Val) variant were
identified. These patients developed multiple colorectal adenomas, of
whom two showed early onset CRC. We can therefore confirm that
POLE variants play a minor but tangible role in familial CRC and
polyposis. Despite an enrichment in our cohort for inherited CRC and
polyposis, the frequency (3 in 1188; 0.25%) is also comparable to the
currently reported frequency.13,14
The first patient (PT1) was diagnosed with a MSI caecum tumour
and two adenomas at age 40. She developed, cumulatively, around 30
polyps and presented with a microsatellite stable endometrial cancer at
age 50. Her son, patient 2 (PT2), is also a carrier of POLE
p.(Leu424Val). In addition, he was clinically diagnosed with neurofi-
bromatosis type I, the latter originating in his father’s family. He
developed a MSI caecum adenocarcinoma at age 30 and was diagnosed
with an astrocytoma at age 15, presumably as a consequence of
neurofibromatosis. Interestingly, a patient with multiple polyps, and
two astrocytomas at age 26, has been described in a family with a
POLD1 variant (family SM6).13
As tumour tissue was available for the POLE p.(Leu424Val) carriers
PT1 and PT2 (mother and son, respectively), we performed IHC for
POLE, MLH1, MSH2, MSH6 and PMS2. Considering that the POLE
exonuclease domain is essential for the maintenance of replication
fidelity, the lack of predictive value of POLE IHC is to be expected, in
contrast to the predictive value for the MMR genes. However, the
availability of tumour tissue from the POLE variant carriers allowed us
to test this. Indeed, both MSI-H tumour tissues showed a positive
nuclear POLE protein expression in tumour cells as compared with
normal cells from the same tissue. POLE IHC therefore does not
appear to be predictive for the effect of the variant.
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The MSI-H caecum tumour from PT1 showed loss of only MSH6
protein expression in tumour cells (Figure 1), whereas the adenocar-
cinoma from PT2 showed loss of both MSH2 and MSH6 protein
expression in tumour cells (Figure 1). The loss of nuclear expression of
MSH6 and MSH6/MSH2 in the tumours from this family is indicative
for Lynch syndrome because of an inherited MSH6 or MSH2 germline
variant. However, no germline variants were found inMSH6 orMSH2,
nor in any of the other MMR genes. We therefore screened PT1 and
PT2 tumours for somatic mutations in MLH1, MSH2, MSH6, PMS2
and also for somatic mutations in APC and TP53 (Table 1). The
mother’s tumour (PT1) showed a hypermutator phenotype, with
multiple somatic mutations in the MMR genes and in APC and
TP53, whereas the adenocarcinoma from PT2 showed no APC or TP53
mutations. Interestingly, PT1 showed three somatic mutations in
MSH6. The first is a pathogenic truncating mutation, c.2629G4T,
p.(Glu877*), the second is a possibly pathogenic missense mutation,
c.4000C4T, p.(Arg1334Trp) that might affect the splice donor site in
exon 9, while the third mutation is probably non-pathogenic,
c.3725G4A, p.(Arg1242His). A single truncating MSH2 mutation,
c.643C4T, p.(Gln215*), was found in the son’s tumour (PT2,
Table 1), although a second hit in MSH2 was not detected. No
somatic mutations were detected in KRAS and BRAF hotspots in the
tumours from PT1 and PT2. These somatic mutations show an excess
of G:C to T:A substitutions, similar to the reported EDM-associated
mutator phenotype.13 No other somatic mutations or previously
undetected germline mutations were found. In light of the hypermu-
tator phenotype associated with POLE mutations, a second point
mutation was to be expected. On the other hand, promoter methyla-
tion or loss of heterozygosity at the MMR locus as the second hit could
explain the loss of MSH2 or MSH6. Recently it was demonstrated that
the loss of heterozygosity accounts for the second hit in over 50% of
MSI tumours, albeit mostly in MLH1 deficient tumours.19
Patient 3 (PT3) was diagnosed with multiple polyps at age 34.
Two of the patient’s brothers were affected with CRC at ages 18 and
Figure 1 HE staining and MSH2, MSH6 and POLE immunohistochemistry (x20) of the MSI-H tumours from POLE variant carriers PT1 and PT2 (one family);
both cases show MSH6 negative staining, with positive stromal cells (brown). PT2 also shows loss of MSH2 in tumour cells.
Table 1 Summary of somatic mutations in colorectal cancer genes in two tumours from POLE p.(Leu424Val) carriers (PT1 and PT2) from one
family
Case Gene.ref gene DNA level (cDNA) Protein Chr Start End Ref Alt Exonic func.ref gene Pathogenic
PT1 MSH6 NM_000179.2:c.2629G4T p.Glu877* 2 48027751 48027751 G T Stopgain SNV Truncating
PT1 MSH6 NM_000179.2:c.2291C4T p.Thr764Ile 2 48027413 48027413 C T Non-synonymous SNV Unlikely pathogenic
PT1 MSH6 NM_000179.2:c.3725G4A p.Arg1242His 2 48033421 48033421 G A Non-synonymous SNV Unknown pathogenicity
PT1 MSH6 NM_000179.2:c.4000C4T p.Arg1334Trp 2 48033789 48033789 C T Non-synonymous SNV Unknown pathogenicity
PT1 MSH2 NM_000251.2:c.49G4A p.Val17Ile 2 47630379 47630379 G A Non-synonymous SNV Unlikely pathogenic
PT1 MLH1 NM_000249.2:c.31C4A p.Leu11Met 3 37035069 37035069 C A Non-synonymous SNV Unknown pathogenicity
PT1 APC NM_000038.5:c.680A4G p.Asp227Gly 5 112128177 112128177 A G Non-synonymous SNV Unknown pathogenicity
PT1 APC NM_000038.5:c.1778G4A p.Trp593* 5 112170682 112170682 G A Stopgain SNV Truncating
PT1 APC NM_000038.5:c.2662G4A p.Ala888Thr 5 112173953 112173953 G A Non-synonymous SNV Unlikely pathogenic
PT1 APC NM_000038.5:c.4540C4T p.Pro1514Ser 5 112175831 112175831 C T Non-synonymous SNV Unlikely pathogenic
PT1 APC NM_000038.5:c.5117C4T p.Ser1706Leu 5 112176408 112176408 C T Non-synonymous SNV Unlikely pathogenic
PT1 APC NM_000038.5:c.8314T4C p.Ser2772Pro 5 112179605 112179605 T C Non-synonymous SNV Unlikely pathogenic
PT1 TP53 NM_000546.5:c.523C4T p.Arg175Cys 17 7578407 7578407 G A Non-synonymous SNV Likely pathogenic
PT1 TP53 NM_000546.5:c.742C4T p.Arg248Trp 17 7577539 7577539 G A Non-synonymous SNV Likely pathogenic
PT1 TP53 NM_000546.5:c.916C4T p.Arg306* 17 7577022 7577022 G A Stopgain SNV Truncating
PT2 MSH2 NM_000251.2:c.643C4T p.Gln215* 2 47637509 47637509 C T Stopgain SNV Truncating
PT2 APC NM_000038.5:c.2045G4A p.Gly682Glu 5 112173336 112173336 G A Non-synonymous SNV Likely pathogenic
No mutations were found in KRAS, BRAF and PMS2.
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37, while a third brother developed liver cancer at age 27. The patient’s
mother died aged 31 because of unknown causes, probably cancer.
Tumour tissue from an adenoma with early cancer and one adenoma
with high-grade dysplasia was available for examination. The adenoma
with cancer (estimated tumour percentage 50%) showed microsatellite
instability and immunohistochemical loss of MSH2 and MSH6
protein staining in the absence of germline variants in MSH2 and
MSH6. A probably non-pathogenic heterozygous missense mutation,
c.1550 C4T, p.(Ala517Val), in the MSH2 gene was detected in the
adenoma with early cancer but not in normal tissue. Testing for
somatic mutations in other genes could not be performed because of
the limited availability of tumour DNA. Hypermethylation of the
MSH2 promoter was not detected in the tumour or normal tissue of
PT3. Microsatellite instability analysis of an adenoma with high-grade
dysplasia, with an estimated percentage of cells with high-grade
dysplasia of 65%, showed no microsatellite instability and normal
staining of the DNA mismatch repair proteins MSH2 and MSH6, as
well as MLH1 and PMS2. Tumour tissue and germline DNA from
relatives of PT3 were not available.
Patient 4 (PT4) was diagnosed with a microsatellite stable colon
cancer and polyposis at the age of 33. No tumour tissue was available
for further analysis. Although a history of CRC was reported in both
paternal and maternal branches of the family, the parents were not
affected by polyposis and did not carry the POLE variant, indicating
that the POLE variant in PT4 was probably de-novo. There was also no
evidence for gonadal mosaicism in the parents; the sibling is not
known to have polyposis. In a recent study, the same POLE variant
was also detected as a de-novo occurrence in a patient with early onset
CRC and polyposis.14
Interestingly, the germline POLE variant in the currently studied
families (PT1, PT2 and PT3) is associated with a Lynch syndrome
phenotype with MSI tumours and MSH6 or MSH2/MSH6 protein loss.
This contrasts with previously identified POLE and POLD1 germline
variant carriers who developed microsatellite stable tumours.13 Somatic
POLE mutations have been reported in both microsatellite stable and
MSI tumours.10,12 The Lynch syndrome phenotype reported here is not
because of the germline variants in the MMR genes but more likely the
result of somatic inactivation (PT1 and PT2). The hypermutator
phenotype associated with inherited POLE mutations suggests a
causative role for the somatic mutations although the second hit could
not be identified. A similar co-occurrence of somatic MMR and POLE
mutations was recently shown in a sequencing effort of 147 CRC
genomes. Eight of the eleven POLE-mutated tumours showed addi-
tional MSH6 somatic mutations, and of these, five cases also showed
MSH2 mutations.12 Moreover, MSI tumours with two somatic MSH2
mutations, lacking MSH2 and MSH6 protein expression,22 or with loss
of MLH1 protein staining in the tumour,23–25 have also been reported
for patients with bi-allelic variants in the base excision repair gene
MUTYH. Similarly to POLE germline variants, MUTYH missense
variants can also induce somatic mutations in MMR genes, although
the mechanism behind the co-occurrence of mutations in the different
DNA repair defects remains elusive.
CONCLUSIONS
The three new families with POLE variants reported here bring the
total number of reported families to 17. We have demonstrated that
POLE germline variants can give rise to a Lynch syndrome-like
phenotype, with MSI-H tumours displaying negative IHC for one of
the MMR genes. IHC for POLE is not helpful in identifying currently
known variants. We now recommend that testing for POLE should be
considered when screening unexplained MSI-H tumours, and while
clinical surveillance of POLE carriers appears to be indicated from a
relatively young age, further conclusions regarding clinical manage-
ment should be based on a larger series than the currently identified
patients.
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